Logo_AIHTA
  • Deutsch
  • Contact
    • Imprint
      • Privacy Notice
        • Newsletter
          • Sitemap
            Menu_button
            • News
              • About us
                • Research areas
                  • Research Projects
                    • Publications
                      • Search
                        • Announcements
                          • Events
                            • Newsletter
                              • Press release on our reports
                                • Press photos
                                  Video
                                  Video: What is HTA?    
                                  • Home
                                  • News

                                  News

                                  Leiste32


                                  Welcome to the homepage of AIHTA!

                                  AIHTA is an academic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.

                                  In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.

                                  Subscribe to newsletter

                                  Fotolia-110033217-von-yodiyim2
                                  ©stock.adobe.com

                                  Announcement

                                  Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer

                                  This update report assesses three alternative treatments to radical therapies for localised prostate cancer (PCA): irreversible electroporation (IRE) uses electrode needles to target and destroy carcinoma tissue; stereotactic radiation therapy (SBRT) and proton therapy (PT) are forms of external beam radiation therapy, SBRT delivers high dose radiation in fewer fractions than conventional or moderate fractionation radiation, while PT delivers high-dose ionizing radiation with great precision.

                                  The current evidence remains insufficient to conclude that IRE, SBRT, and PT improve outcomes in terms of survival and quality of life, as well as the avoidance of radical invasive procedures like prostatectomy, compared to conventional therapies. Recent RCTs on SBRT show minor differences in survival rates compared to conventional fractionation radiation in low- and intermediate-risk PCa. Further research is necessary for definitive conclusions.

                                  Publication: Project Report No.: 107/1. Update: https://eprints.aihta.at/1530/
                                  Contact: Judit Erdös

                                  More...

                                  Newsletter_preview

                                  Newsletter

                                  Note: this content is only available in German.

                                  Inhalt

                                  • Editorial: HTA-Patient*innenschulungen in EUCAPA
                                  • Thermoablation von benignen Schilddrüsenknoten
                                  • Perkutane transluminale Koronarangioplastie mit medikamentenbeschichtetem Ballon bei koronarer Herzkrankheit
                                  • Elektrokonvulsionstherapie bei therapieresistenter Depression und therapieresistenter Schizophrenie
                                  • Renale Denervierung bei therapieresistenter Hypertonie
                                  • Perkutaner transfemoraler heterotoper Trikuspidalklappenersatz bei Trikuspidalinsuffizienz
                                  • Termine
                                  • Themen-Vorschau
                                  Print Zur Druckversion...
                                  2429
                                  ©stock.adobe.com

                                  Announcement

                                  Evaluation of individual medical procedures - Reports 2024

                                  We are pleased to introduce our new reports.

                                  Decision Support Documents 2024:

                                  • DSD 139: Caval valve implantation for severe tricuspid regurgitation https://eprints.aihta.at/1525
                                  • DSD 140: Electroconvulsive therapy in treatment-resistant depression and treatment-resistant schizophrenia https://eprints.aihta.at/1526
                                  • DSD 141: Thermoablation for benign thyroid nodules https://eprints.aihta.at/1527

                                  + 2 Updates

                                  • DSD 24: Percutaneous transluminal coronary angioplasty (PTCA) with drug-eluting balloon (DEB) in patients with coronary artery disease (CAD). 3. Update 2024 https://eprints.aihta.at/1528
                                  • DSD 45: Renal denervation (RDN) in patients with treatment resistant hypertension. 2. Update 2024 https://eprints.aihta.at/1529

                                  More...

                                  Adobestock-1923936581
                                  ©stock.adobe.com

                                  Announcement

                                  Point of Care Tests (POCT): D-Dimer and Troponin. Update 2024

                                  Point of care tests (POCTs) for troponin (Tn) and D-Dimer enable rapid diagnostics near patients. Tn-POCTs are used when there is a suspicion of acute coronary syndrome (ACS) and D-Dimer-POCTs are used when there is a suspicion of venous thromboembolism (VTE).

                                  The aim of this report is to evaluate the clinical utility of the two POC diagnostics, D-Dimer and troponin, in primary care.

                                  Publication: HTA Project Report No. 124, 1. Update 2024: https://eprints.aihta.at/1524/
                                  Contact: Claudia Wild

                                   

                                  More...

                                  2192
                                  ©stock.adobe.com

                                  Announcement

                                  Horizon Scanning in Oncology - Fact Sheets

                                  We are pleased to introduce you three new Fact Sheets.

                                  Fact Sheet No. 177 (May 2024)
                                  Sugemalimab (Cejemly®) with platinum-based chemotherapy for the first?line treatment of metastatic non-small-cell lung cancer (NSCLC)

                                  Fact Sheet No. 178 (May 2024)
                                  Osimertinib (Tagrisso®) with pemetrexed and platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC) 

                                  Fact Sheet No. 179 (May 2024)
                                  Tislelizumab (Tevimbra®) monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) 

                                  More...

                                  Newsletter_preview

                                  Newsletter

                                  Note: this content is only available in German.

                                  Inhalt

                                  • Editorial: Neue Methoden aus der Gesundheitsökonomie machen Auswirkungen neuer Leistungen auf gesundheitliche Ungleichheit sichtbar
                                  • Pharmakogenetik: personalisierte Verschreibungen
                                  • Hautkrebsprävention: Leitlinien-Empfehlungen zur Primär- und Sekundärprävention
                                  • Gentests bei familiärer Hypercholesterinämie
                                  • Fernüberwachung bei chronischen körperlichen Erkrankungen
                                  • Termine
                                  • Themen-Vorschau
                                  Print Zur Druckversion...
                                  2191
                                  ©stock.adobe.com

                                  Announcement

                                  Horizon Scanning in Oncology - Fact Sheets

                                  We are pleased to introduce you six new Fact Sheets.

                                  Fact Sheet No. 171 (April 2024)
                                  Fruquintinib (Fruzaqla®) as monotherapy for the treatment of metastatic colorectal cancer (mCRC)

                                  Fact Sheet No. 172 (April 2024)
                                  Capivasertib (Truqap®) with fulvestrant for the treatment ER-positive, HER2 negative locally advanced or metastatic breast cancer

                                  Fact Sheet No. 173 (April 2024)
                                  Alectinib (Alecensa®) as adjuvant treatment following complete tumour resection for adult patients with ALK positive non-small cell lung cancer (NSCLC)

                                  Fact Sheet No. 174 (April 2024)
                                  Nivolumab (Opdivo®) in combination with cisplatin and gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma

                                  Fact Sheet No. 175 (April 2024)
                                  Entrectinib (Rozlytrek®) as monotherapy for the treatment of solid tumours with a NTRK gene fusion

                                  Fact Sheet No. 176 (April 2024)
                                  Amivantamab (Rybrevant®) with carboplatin and pemetrexed for the first line treatment of advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations

                                  More...

                                  Newsletter_preview

                                  Newsletter

                                  Note: this content is only available in German.

                                  Inhalt

                                  • Editorial: AIHTA-Framework erleichtert Identifikation öffentlicher Beiträge zur Entwicklung von Innovationen im Gesundheitswesen
                                  • Biofeedback-Therapie bei Migräne
                                  • Preis- und Kostenentwicklung von Orphan Drugs
                                  • Modelle der primären Gesundheitsversorgung für Obdachlose
                                  • CAR-basierte Immuntherapie mit Fokus auf CAR-NK-Zellen
                                  • Termine
                                  • Themen-Vorschau
                                  Print Zur Druckversion...
                                  Bild-weight-stigma-ki-generiert
                                  AI generated

                                  Project / Prevention and screening, Psychological & psychiatric interventions

                                  Strategies to reduce weight stigmatisation of people with overweight or obesity in the healthcare sector

                                  Project leaders: Sarah Wolf

                                  Project team: Sarah Wolf, Julia Kern

                                  Duration: Mid-April 2024 until Mid-November 2024
                                  Language: German (with English executive summary)
                                  Publication: HTA Project Report No. 160: https://eprints.aihta.at/1547/

                                  More...

                                  2189
                                  ©stock.adobe.com

                                  Announcement

                                  Horizon Scanning in Oncology - Fact Sheets

                                  We are pleased to introduce you three new Fact Sheets.

                                  Fact Sheet No. 168 (March 2024)
                                  Irinotecan hydrochloride trihydrate (Onivyde® pegylated liposomal) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas

                                  Fact Sheet No. 169 (March 2024)
                                  Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced rearranged during transfection (RET) fusion-positive solid tumours

                                  Fact Sheet No. 170 (March 2024)
                                  Enzalutamide (Xtandi®) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC)

                                  More...

                                  « < 1 2 3 4 5 ... > »
                                  Displaying results 21 to 30.
                                  • News
                                    • Announcements
                                      • Events
                                        • Newsletter
                                          • Press release on our reports
                                            • Press photos
                                            • About us
                                              • Evaluation
                                                • History
                                                  • Methods
                                                    • Team
                                                      • Shareholder & organization chart
                                                        • Stakeholder involvement
                                                          • Press clippings
                                                          • Research areas
                                                            • Oncology
                                                              • High tech medicine
                                                                • Rehabilitation and occupational therapy
                                                                  • Prevention and screening
                                                                    • Psychological & psychiatric interventions
                                                                      • Health economics
                                                                        • European collaboration
                                                                          • HTA-methods & steering instruments
                                                                            • Complementary medicine
                                                                            • Research Projects
                                                                              • Synopsis of current research projects
                                                                                • Synopsis of completed research projects
                                                                                  • Decision Support Documents for the Austrian Appraisal Board
                                                                                    • HTA-Information Service Rapid Reviews
                                                                                      • Horizon Scanning in Oncology – Prioritisation of new and emerging oncologic drugs
                                                                                        • Horizon Scanning of Medicines - Reports and Fact Sheets
                                                                                          • Horizon Scanning in Oncology – support for a budget-impact-calculation
                                                                                            • Evaluation of individual medical procedures - Reports
                                                                                              • All projects in an overview
                                                                                              • Publications
                                                                                                • Repository
                                                                                                  • HTA-Newsletter
                                                                                                    • Annual Reports
                                                                                                    • Search
                                                                                                      Netzwerk
                                                                                                      • Eunethta
                                                                                                      • Ebm
                                                                                                      • Inahta
                                                                                                      • Dexhelpp
                                                                                                      Shareholder
                                                                                                      • Bmfg
                                                                                                      • Sv
                                                                                                      • Wgfond
                                                                                                      • Noe
                                                                                                      • Ooghfond
                                                                                                      • Ghls
                                                                                                      • Tirol
                                                                                                      • Vorarlberg
                                                                                                      • Kghfond
                                                                                                      • Ghpf
                                                                                                      • Burgef
                                                                                                      • Contact
                                                                                                        • Imprint
                                                                                                          • Privacy Notice
                                                                                                            • Newsletter
                                                                                                              • Sitemap
                                                                                                                © 2025 HTA Austria - Austrian Institute for Health Technology Assessment GmbH. Alle Rechte vorbehalten.
                                                                                                                • Log in